Menorrhagia

Author: Julia A Shaw, MD, MBA, FACOG, Assistant Clinical Professor and Associate Program Director, Department of Obstetrics and Gynecology, Yale School of Medicine; Medical Director, Yale-New Haven Hospital Women's Center
Coauthor(s): Howard A Shaw, MD, MBA, Associate Professor of Obstetrics and Gynecology, University of Connecticut; Chairman/Director, Residency Program Director, Department of Obstetrics and Gynecology; Chief Quality Officer, St Francis Hospital and Medical Center

Introduction

Background

Menorrhagia is defined as menstruation at regular cycle intervals but with excessive flow and duration and is one of the most common gynecologic complaints in contemporary gynecology. Clinically, menorrhagia is defined as total blood loss exceeding 80 mL per cycle or menses lasting longer than 7 days.1 The World Health Organization reports that 18 million women aged 30-55 years perceive their menstrual bleeding to be exorbitant.2 Reports show that only 10% of these women experience blood loss severe enough to cause anemia or be clinically defined as menorrhagia.1 ,3 ,4 In practice, measuring menstrual blood loss is difficult. Thus, the diagnosis is usually based upon the patient's history.

A normal menstrual cycle is 21-35 days in duration, with bleeding lasting an average of 7 days and flow measuring 25-80 mL.5

Menorrhagia must be distinguished clinically from other common gynecologic diagnoses. These include metrorrhagia (flow at irregular intervals), menometrorrhagia (frequent, excessive flow), polymenorrhea (bleeding at intervals <21 d), and dysfunctional uterine bleeding (abnormal uterine bleeding without any obvious structural or systemic abnormality).5

Nearly 30% of all hysterectomies performed in the United States are performed to alleviate heavy menstrual bleeding.6 Historically, definitive surgical correction has been the mainstay of treatment for menorrhagia. Modern gynecology has trended toward conservative therapy both for controlling costs and the desire of many women to preserve their uterus.

Heavy menstrual bleeding is a subjective finding, making the exact problem definition difficult. Treatment regimens must address the specific facet of the menstrual cycle the patient perceives to be abnormal, (ie, cycle length, quantity of bleeding). Finally, treatment success is usually evaluated subjectively by each patient, making positive outcome measurement difficult.

Pathophysiology

Knowledge of normal menstrual function is imperative in understanding the etiologies of menorrhagia. Four phases constitute the menstrual cycle, follicular, luteal, implantation, and menstrual.

In response to gonadotropin-releasing hormone (GnRH) from the hypothalamus, the pituitary gland synthesizes follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which induce the ovaries to produce estrogen and progesterone.

During the follicular phase, estrogen stimulation results in an increase in endometrial thickness. This also is known as the proliferative phase.

The luteal phase is intricately involved in the process of ovulation. During this phase, also known as the secretory phase, progesterone causes endometrial maturation.

If fertilization occurs, the implantation phase is maintained. Without fertilization, estrogen and progesterone withdrawal results in menstruation.

Etiologic causes are numerous and often unknown. Factors contributing to menorrhagia can be sorted into several categories, including organic, endocrinologic, anatomic, and iatrogenic.

If the bleeding workup does not provide any clues to the etiology of the menorrhagia, a patient often is given the diagnosis of dysfunctional uterine bleeding (DUB). Most cases of DUB are secondary to anovulation. Without ovulation, the corpus luteum fails to form, resulting in no progesterone secretion. Unopposed estrogen allows the endometrium to proliferate and thicken. The endometrium finally outgrows its blood supply and degenerates. The end result is asynchronous breakdown of the endometrial lining at different levels. This also is why anovulatory bleeding is heavier than normal menstrual flow.

Hemostasis of the endometrium is directly related to the functions of platelets and fibrin. Deficiencies in either of these components results in menorrhagia for patients with von Willebrand disease or thrombocytopenia. Thrombi are seen in the functional layers but are limited to the shedding surface of the tissue. These thrombi are known as "plugs" because blood can only partially flow past them. Fibrinolysis limits the fibrin deposits in the unshed layer. Following thrombin plug formation, vasoconstriction occurs and contributes to hemostasis.

Anatomic defects or growths within the uterus can alter either of the aforementioned pathways (endocrinologic/hemostatic), causing significant uterine bleeding. The clinical presentation is dependent on the location and size of the gynecologic lesion.

Organic diseases also contribute to menorrhagia in the female patient. For example, in patients with renal failure, gonadal resistance to hormones and hypothalamic-pituitary axis disturbances result in menstrual irregularities. Most women in this renal state are amenorrheic, but others also develop menorrhagia. If uremic coagulopathy ensues, it usually is due to platelet dysfunction and abnormal factor VIII function. The resulting prolonged bleeding time causes menorrhagia that can be very tenuous to treat.

Due to the overwhelming factors that can contribute to the dysfunction of either the endocrine or hematological pathways, in-depth knowledge of an existing organic disease is just as imperative as understanding the menstrual cycle itself.

Frequency

United States

While menorrhagia remains a leading reason for gynecologic office visits, only 10-20% of all menstruating women experience blood loss severe enough to be defined clinically as menorrhagia.4

Mortality/Morbidity

Infrequent episodes of menorrhagia usually do not carry severe risks to women's general health.

  • Patients who lose more than 80 mL of blood, especially repetitively, are at risk for serious medical sequelae. These women are likely to develop iron-deficiency anemia as a result of their blood loss. Menorrhagia is the most common cause of anemia in premenopausal women. This usually can be remedied by simple ingestion of ferrous sulfate to replace iron stores. If the bleeding is severe enough to cause volume depletion, patients may experience shortness of breath, fatigue, palpitations, and other related symptoms. This level of anemia necessitates hospitalization for intravenous fluids and possible transfusion and/or intravenous estrogen therapy. Patients who do not respond to medical therapy may require surgical intervention to control the menorrhagia.
  • Other sequelae associated with menorrhagia usually are related to the etiology. For example, with hypothyroidism, patients may experience symptoms associated with a low-functioning thyroid (eg, cold intolerance, hair loss, dry skin, weight gain) in addition to the effects of significant blood loss.7

Sex

Only females are affected by menorrhagia.

Age

Any woman of reproductive age who is menstruating may develop menorrhagia. Most patients with menorrhagia are older than 30 years.5 This is because the most common cause of heavy menses in the younger population is anovulatory cycles, in which bleeding does not occur at regular intervals.8

Clinical

History

Symptoms related by a patient with menorrhagia often can be more revealing than laboratory tests. Considering the lengthy list of possible etiologies that contribute to menorrhagia, taking a detailed patient history is imperative. Inquiries should include the following:

  • Exclusion of pregnancy
    • This is the most common cause of irregular bleeding in women of reproductive age.
    • Pregnancy should be the first diagnosis to be excluded before further testing or medications are instituted.
  • Quantity and quality of bleeding
    • Quantity is a very subjective issue when considering vaginal bleeding. Best estimates usually are the only source clinicians have available to consider. Helpful references for totaling blood loss may include that the average tampon holds 5 mL and the average pad holds 5-15 mL of blood. Asking the patient what type of pad (liner vs overnight) was used and if it was soaked may add some insight into what the patient believes to be heavy bleeding.
    • Quality of bleeding involves the presence of clots and their size.
  • Age
    • Young patients, from menarche to the late-teen years, most commonly have anovulatory bleeding due to the immaturity of their hypothalamic-pituitary axis. If bleeding does not respond to usual therapy in this age group, a bleeding disorder must be considered.
    • Women aged 30-50 years may have organic or structural abnormalities. Fibroids or polyps are frequent anatomical findings. Organic causes can be anything from thyroid dysfunction to renal failure.
    • Postmenopausal women with any uterine bleeding should receive an immediate workup for endometrial cancer .
    • Endometrial hyperplasia must be considered in women who are obese, aged 70 or older, nulliparous, or have diabetes.
  • Pelvic pain and pathology
    • Knowing if a patient has any long-standing diagnosis or known pathology (eg, fibroids) is helpful.
    • Records from other physicians or hospitalizations may prevent redundancy in ordering lab work or diagnostic imaging.
  • Menses pattern from menarche
    • If a young patient has had irregular menses since menarche, the most common etiology of her bleeding is anovulation.
    • Anovulatory bleeding is most common in young girls (aged 12-18 y) and common in obese females of any reproductive age.
    • If a patient's bleeding normally occurs at regular intervals and the irregularity is new in onset, pathology must be ruled out, regardless of age.
  • Sexual activity
    • Simple vaginitis (eg, candidal, bacterial vaginosis) may cause intermenstrual bleeding, while gonorrhea and chlamydia may present with heavier bleeding attributed primarily to the copious discharge mixed with the blood.
    • Chlamydia is a common cause of postpartum endometritis, leading to vaginal bleeding in the weeks following a delivery.
    • A postpartum infection (eg, endometritis ) also may be due to organisms unrelated to sexual activity.
  • Contraceptive use (intrauterine device or hormones)
    • Commonly, an intrauterine device (IUD) causes increased uterine cramping and menstrual flow.
    • If a patient has recently discontinued birth control pills, she may return to her "natural" menses and report an increase in flow. This actually is normal because most oral birth control pills decrease the flow and duration of a woman's menses.
  • Presence of hirsutism (polycystic ovarian syndrome)
    • These patients commonly are obese and in an anovulatory state. When they do have a period, it may be very heavy and cause concern for the patient.
    • The etiology of this is explained in the Introduction to this article.
  • Galactorrhea (pituitary tumor): Any patient complaining of a milky discharge from either breast (while not pregnant, postpartum, or breastfeeding) needs a prolactin level to rule out a pituitary tumor.
  • Systemic illnesses (hepatic/renal failure or diabetes)
    • As explained in the Introduction , organic diseases may affect either the hormonal or hematologic pathways that are involved in the manifestation of menorrhagia.
    • If either the hypothalamic-pituitary axis or the coagulation paths are disrupted, heavy bleeding may result.
  • Symptoms of thyroid dysfunction: The alteration of the hypothalamic-pituitary axis may create either amenorrhea (hyperthyroidism) or menorrhagia (hypothyroidism).
  • Excessive bruising or known bleeding disorders
    • This is especially important in a young patient who does not stop bleeding during her first menses.
    • This is a very common presentation for an undiagnosed bleeding disorder (von Willebrand disease) in a young girl.
  • Current medications (hormones or anticoagulants)
    • Any medication that prolongs bleeding time may cause menorrhagia.
    • A patient treated with any progestin therapy may have a withdrawal bleed after cessation of the medication. This bleeding often is heavy and worrisome to patients if they are not forewarned.
  • Previous medical or surgical procedures/diagnoses: This also is helpful in preventing duplication of testing.

Physical

The physical examination should be tailored to the differential diagnoses formulated by the results of the patient's history.

  • Initial inspection should include evaluation for the following:
    • Signs of severe volume depletion (eg, anemia): This may help confirm the patient's history of very heavy bleeding and/or prompt immediate inpatient care.
    • Obesity: This is an independent risk factor for endometrial cancer. Adipose tissue is a locale for estrogen conversion. Therefore, the larger the patient, the more increased the risk (and the higher the unopposed estrogen level on the endometrium).
    • Signs of androgen excess (eg, hirsutism): This usually points to polycystic ovarian syndrome (PCOS), leading to anovulatory bleeding (see Presence of hirsutism ).
    • Ecchymosis: This usually is a sign of trauma or a bleeding disorder.
    • Purpura: This also is a sign of trauma or a possible bleeding disorder.
    • Pronounced acne: This is a sign of PCOS.
  • General examination should include evaluation of the following:
    • Visual fields
    • Bleeding gums
    • Thyroid evaluation
    • Galactorrhea
    • Enlarged liver or spleen
  • Pelvic examination should evaluate for the presence of external genital lesions.
  • Vaginal/cervical discharge: Look for a copious discharge indicating infection, and confirm the actual site of the bleeding (if present). Assess as follows:
    • Uterine size, shape, and contour: An enlarged irregularly shaped uterus suggests fibroids if the patient is aged 30-50 years. An enlarged uniformly shaped uterus in a postmenopausal patient with bleeding suggests endometrial cancer until proven otherwise.
    • Cervical motion tenderness: This is a common symptom of pelvic inflammatory disease (PID) that usually is caused by gonorrhea or chlamydia. This is an important diagnosis to exclude, especially in young nulliparous women, because it can lead to pelvic adhesions and infertility.
    • Adnexal tenderness or masses: This is especially concerning in patients older than 40 years. Ovarian cancer may present with intermenstrual bleeding as its only symptom. Rare but deadly ovarian tumors also can present in teenage girls. Any suspicion of an adnexal mass should prompt an immediate pelvic ultrasound.

Causes

Etiologies of menorrhagia are divided into 4 categories, organic, endocrinologic, anatomic, and iatrogenic.

  • Organic causes of menorrhagia include infection, bleeding disorders, and organ dysfunction.
    • Infections can be of any genitourinary origin. The aforementioned sexually transmitted diseases are of greater concern in the teenage and early adult population. Bleeding from the urethra or rectum always must be considered in the workup, especially in the postmenopausal woman who has negative findings after a workup for vaginal bleeding.
    • Coagulation disorders can evade diagnosis until menarche, when heavy menstrual bleeding presents as an unrelenting disorder. These include von Willebrand disease; factor II, V, VII, and IX deficiencies; prothrombin deficiency; idiopathic thrombocytopenia purpura (ITP); and thromboasthenia.9 See more on bleeding disorders below .
    • Organ dysfunction causing menorrhagia includes hepatic or renal failure. Chronic liver disease impairs production of clotting factors and reduces hormone metabolism (eg, estrogen). Either of these problems may lead to heavy uterine bleeding.
  • Endocrine causes of menorrhagia include thyroid and adrenal gland dysfunction, pituitary tumors, anovulatory cycles, PCOS , obesity, and vasculature imbalance.
    • Both hypothyroidism and hyperthyroidism result in menorrhagia. Even subclinical cases of hypothyroidism produce heavy uterine bleeding in 20% of patients. Menorrhagia usually resolves with correction of the thyroid disorder.7
    • Prolactin-producing pituitary tumors cause menorrhagia by disrupting (GnRH) secretion. This leads to decreased LH and FSH levels, which ultimately cause hypogonadism. Interim stages of menorrhagia result until hypogonadism manifests.
    • The most common etiology of heavy uterine bleeding is anovulatory cycles. The finding of menorrhagia at irregular intervals without any known organic etiology confirms the clinical diagnosis. This is most common in adolescent and perimenopausal populations.
    • The hallmarks of PCOS are anovulation, irregular menses, obesity, and hirsutism. Insulin resistance is common and increases androgen production by the ovaries.
    • Hyperinsulinemia is a direct consequence of obesity. This overproduction of insulin leads to ovarian production of androgens, as occurs in PCOS.
    • Vasculature imbalance is theorized to be the result of a discrepancy between the vasoconstricting and aggregating actions of prostaglandin F2 (alpha) and thromboxane A2 and the vasodilating actions of prostaglandin E2 and prostacyclin on the myometrial and endometrial vasculature.
  • Anatomic etiologies for menorrhagia include uterine fibroids, endometrial polyps, endometrial hyperplasia, and pregnancy.
    • Fibroids and polyps are benign structures that distort the uterine wall and/or endometrium. Either may be located within the uterine lining, but fibroids may occur almost anywhere on the uterus.
    • The mechanism by which endometrial polyps or fibroids cause menorrhagia is not well understood. The blood supply to the fibroid or polyp is different compared to the surrounding endometrium and is thought to function independently. This blood supply is greater than the endometrial supply and may have impeded venous return, causing pooling in the areas of the fibroid. Heavy pooling is thought to weaken the endometrium in that area, and break-through bleeding ensues.
    • Fibroids located within the uterine wall may inhibit muscle contracture, thereby preventing normal uterine attempts at hemostasis. This also is why intramural fibroids may cause a significant amount of pain and cramping. Fibroids may enlarge to the point that they outgrow their blood supply and undergo necrosis. This also causes a great deal of pain for patients.
    • Endometrial hyperplasia usually results from unopposed estrogen production, regardless of the etiology. Endometrial hyperplasia can lead to endometrial cancer in 1-2% of patients with anovulatory bleeding, but it is a diagnosis of exclusion in postmenopausal bleeding (average age at menopause is 51 y). If a woman takes unopposed estrogen (without progesterone), her relative risk of endometrial cancer is 2.8 compared to nonusers.10
    • Iatrogenic causes of menorrhagia include IUDs, steroid hormones, chemotherapy agents, and medications (eg, anticoagulants).
    • IUDs can cause increased menstrual bleeding and cramping due to local irritation effects.
    • Steroid hormones and chemotherapy agents disrupt the normal menstrual cycle, which is restored easily upon cessation of the products.
    • Anticoagulants decrease clotting factors needed to cease any normal blood flow, including menses. This type of menorrhagia also is easily reversible.

Bleeding disorders

An international expert panel including obstetrician/gynecologists and hematologists has issued guidelines to assist physicians in better recognizing bleeding disorders, such as von Willebrand disease, as a cause of menorrhagia and postpartum hemorrhage and to provide disease-specific therapy for the bleeding disorder.11 Historically, a lack of awareness of underlying bleeding disorders has led to underdiagnosis in women with abnormal reproductive tract bleeding. The panel provided expert consensus recommendations on how to identify, confirm, and manage a bleeding disorder. An underlying bleeding disorder should be considered when a patient has any of the following:

  • Menorrhagia since menarche
  • Family history of bleeding disorders
  • Personal history of 1 or more of the following:
    • Notable bruising without known injury
    • Bleeding of oral cavity or gastrointestinal tract without obvious lesion
    • Epistaxis greater than 10 minutes duration (possibly necessitating packing or cautery)

If a bleeding disorder is suspected, consultation with a hematologist is suggested.

Differential Diagnoses

Abortion
Hyperthyroidism
Adnexal Tumors
Hypothyroidism
Adrenal Adenoma
Obesity
Adrenal Carcinoma
Pelvic Inflammatory Disease
Anovulation
Pituitary Microadenomas
Cervicitis
Pregnancy Diagnosis
Endometrial Carcinoma
Uterine Cancer
Endometritis
Vaginitis
Gestational Trophoblastic Neoplasia
 
Hyperprolactinemia
 

Other Problems to Be Considered

Coagulation disorders
Endometrial polyps
Genitourinary infection
Intrauterine device
Liver disease/failure
Medications
Renal disease/failure
Steroid hormones
Uterine fibroids
Vascular imbalance

Workup

Laboratory Studies

  • CBC count
    • The CBC count may be used as a baseline for hemoglobin and hematocrit or to rule out anemia.
    • Use the platelet count in conjunction with a peripheral smear if a coagulation defect is suspected.
  • Iron studies: Total iron-binding capacity (TIBC) and total iron are used to assess iron stores.
  • Coagulation factors: These studies are used to rule out von Willebrand disease; ITP; and factor II, V, VII, or IX deficiency. These tests should be ordered sparingly because they are expensive tests for rare disorders (usually in the adolescent age group).12
  • Human chorionic gonadotropin: Pregnancy remains the most common cause of abnormal uterine bleeding in patients of reproductive age. Bleeding usually denotes threatened abortion, incomplete abortion, or ectopic pregnancy.
  • Thyroid function tests and prolactin level: These tests can rule out hyperthyroidism or hypothyroidism and hyperprolactinemia. All of these conditions cause ovarian dysfunction leading to possible menorrhagia.
  • Liver function and/or renal function tests
    • Order liver function tests (LFTs) when liver disease is suspected, such as in persons with alcoholism or hepatitis.
    • BUN and creatinine tests assess renal function.
    • Dysfunction of either organ can alter coagulation factors and/or the metabolism of hormones.
  • Hormone assays
    • LH, FSH, and androgen levels help diagnose patients with suspected PCOS.
    • Adrenal function tests (eg, cortisol, 17-alpha hydroxyprogesterone [17-OHP]) delineate hyperandrogenism in women with suspected adrenal tumors. Congenital adrenal hyperplasia (CAH) is diagnosed primarily by testing 17-OHP.

Imaging Studies

  • Small, focal, irregular, or eccentrically located endometrial lesions may be missed by an in-office endometrial biopsy (EMB). The findings yielded from pelvic examinations may be limited if patients are obese. These limitations can lead to further imaging studies to inspect the uterus, endometrium, and/or adnexa.
  • Pelvic ultrasound is the best noninvasive imaging study to assess uterine shape, size, and contour; endometrial thickness; and adnexal areas.13
  • Sonohysterography (saline-infusion sonography): Fluid infused into the endometrial cavity enhances intrauterine evaluation. One advantage is the ability to differentiate polyps from submucous leiomyomas (ie, fibroids).

Other Tests

  • Papanicolaou (Pap) smear test results for cervical cytology should be current.
  • Cervical specimens should be obtained if the patient is at risk for an infection.

Procedures

  • Because routine EMB and conventional imaging studies may miss small or laterally displaced lesions, superior methods of assessment must be used in high-risk patients. In addition, performing an in-office biopsy or imaging studies may be limited by patient problems such as obesity or cervical stenosis.
  • Hysteroscopy: This can be done in the office but may require anesthesia if the patient has a low pain tolerance or adequate visualization is not obtainable.
    • This technique is used to directly visualize the endometrial cavity by close contact.
    • A biopsy sample should be taken, regardless of the endometrial appearance.
    • The histologic diagnosis is missed in less than 2% of patients who undergo hysteroscopy with directed biopsy.14
  • Endometrial biopsy
    • This procedure is used in women who are at risk for endometrial carcinoma, polyps, or hyperplasia.
    • High-risk patients who should be biopsied include those with hypertension, diabetes, chronic anovulation (eg, PCOS), obesity, atypical glandular cells (AGUS) on Pap smear, new-onset menorrhagia, and those older than 70 years or any woman older than 35 years with new-onset irregular bleeding (especially if nulliparous).
    • EMB findings are used to assess the stage and proliferation of the endometrial stroma and glands. Many studies have been done to compare the results of EMB and dilatation and curettage (D&C). Both tests are accepted as equal in value and are approximately 98% accurate.14

Histologic Findings

Understanding EMB results is essential for any physician treating menorrhagia.

If no tissue is returned after an EMB is performed, most likely the endometrium is atrophic and requires estrogen.

Simple proliferative endometrium is normal and does not require treatment.

Endometrial hyperplasia (except atypical adenomatous) requires progesterone on timed 12-day regimens outlined in the Treatment . Endometrial hyperplasia with atypia (especially atypical adenomatous hyperplasia) generally is considered equivalent to an intraepithelial malignancy, and hysterectomy usually is advised.

Any biopsy that reveals endometrial carcinoma should prompt immediate referral to a gynecologic oncologist for treatment outlined by current oncology protocols associated with the grade and stage of the cancer.

Treatment

Medical Care

Medical therapy for menorrhagia should be tailored to the individual. Factors taken into consideration when selecting the appropriate medical treatment include the patient's age, coexisting medical diseases, family history, and desire for fertility. Medication cost and adverse effects are also considered because they may play a direct role in patient compliance.15

  • Nonsteroidal anti-inflammatory drugs
    • Nonsteroidal anti-inflammatory drugs (NSAIDs) are the first-line medical therapy in ovulatory menorrhagia.
    • Studies show an average reduction of 20-46% in menstrual blood flow.16
    • NSAIDs reduce prostaglandin levels by inhibiting cyclooxygenase and increasing the ratio of prostacyclin to thromboxane.
    • NSAIDs are ingested for only 5 days of the entire cycle, limiting their most common adverse effect of stomach upset.
  • Oral contraceptive pills
    • Oral contraceptive pills (OCPs) are a popular first-line therapy for women who desire contraception.
    • Menstrual blood loss is reduced as effectively as NSAID's secondary to endometrial atrophy.17
    • OCPs suppress pituitary gonadotropin release, preventing ovulation.
    • Common adverse effects include breast tenderness, breakthrough bleeding, nausea, and, possibly, related weight gain in some individuals.
  • Progestin therapy
    • Progestin is the most frequently prescribed medicine for menorrhagia.
    • Therapy with progestin results in a significant reduction in menstrual blood flow when used alone.
    • Progestin works as an antiestrogen by minimizing the effects of estrogen on target cells, thereby maintaining the endometrium in a state of down-regulation.
    • Common adverse effects include weight gain, headaches, edema, and depression.
  • Levonorgestrel intrauterine system
    • Reduces menstrual blood loss by as much as 97%18
    • Comparable to transcervical resection of the endometrium for reduction of menstrual bleeding19
    • The FDA approved a new indication for the levonorgestrel intrauterine device, Mirena, for the treatment of menorrhagia in women who use intrauterine conception. Approval was granted subsequent to a randomized, open-label, active-control (medroxyprogesterone) clinical trial of women (n=160) with established heavy menstrual bleeding. The results demonstrated that Mirena reduced menstrual blood loss significantly compared with medroxyprogesterone (p<0.001). Adverse effects of Mirena include uterine bleeding or spotting, headache, ovarian cysts, vaginitis, dysmenorrhea, and breast tenderness.20
  • Gonadotropin-releasing hormone agonists
    • These agents are used on a short-term basis due to high costs and severe adverse effects.
    • GnRH agonists are effective in reducing menstrual blood flow.
    • They inhibit pituitary release of FSH and LH, resulting in hypogonadism.
    • A prolonged hypoestrogenic state leads to bone demineralization and reduction of high-density lipoprotein (HDL) cholesterol.
  • Danazol
    • Danazol competes with androgen and progesterone at the receptor level, causing amenorrhea in 4-6 weeks.
    • Androgenic effects cause acne, decreasing breast size, and, rarely, lower voice.
  • Conjugated estrogens
    • These agents are given intravenously every 4 hours in patients with acute bleeding.
    • A D&C procedure may be necessary if no response is noted in 24 hours.
    • If menses slows, follow up with estrogen-progestin therapy for 7 days. This is followed by OCPs for 3 months.

Surgical Care

Surgical management has been the standard of treatment in menorrhagia due to organic causes (eg, fibroids) or when medical therapy fails to alleviate symptoms. Surgical treatment ranges from a simple D&C to a full hysterectomy.

Dilatation and curettage

A D&C should be used for diagnostic purposes. It is not used for treatment because it provides only short-term relief, typically 1-2 months.

This procedure is used best in conjunction with hysteroscopy to evaluate the endometrial cavity for pathology.

It is contraindicated in patients with known or suspected pelvic infection. Risks include uterine perforation, infection, and Asherman syndrome.

Resectoscopic endometrial ablation techniques

  • Transcervical resection of the endometrium21
    • Transcervical resection of the endometrium (TCRE) has been considered the criterion standard cure for menorrhagia for many years.
    • This procedure requires the use of a resectoscope (ie, hysteroscope with a heated wire loop), and it requires time and skill.
    • The primary risk is uterine perforation.
  • Roller-ball endometrial ablation22
    • Roller-ball endometrial ablation essentially is the same as TCRE, except that a heated roller ball is used to destroy the endometrium (instead of the wire loop).
    • It has the same requirements, risks, and outcome success as TCRE.
    • Satisfaction rates are equal to those of TCRE.
  • Endometrial laser ablation
    • Endometrial laser ablation requires Nd:YAG equipment and optical fiber delivery system.
    • The laser is inserted into the uterus through the hysteroscope while transmitting energy through the distending media to warm and eventually coagulate the endometrial tissue.
    • Disadvantages include the expense of the equipment (high), the time required for the procedure (long), and the risk of excessive fluid uptake from the distending media infusion and irrigating fluid.
    • This technique has largely been replaced by the nonresectoscopic systems (discussed below).

Nonresectoscopic endometrial ablation techniques

  • Thermal balloon therapy23 ,24
    • A balloon catheter filled with isotonic sodium chloride solution is inserted into the endometrial cavity, inflated, and heated to 87°C for 8 minutes.
    • Uterine balloon therapy cannot be used in irregular uterine cavities because the balloon will not conform to the cavity.
    • Studies report a 90% satisfaction rate and a 25% amenorrhea rate. Long-term studies are ongoing.
  • Heated free fluid25
    • HydroThermAblator (HTA) is an office procedure in which normal saline is infused into the uterus via the hysteroscope.
    • The solution is heated to 194°F (90°C) for 10 minutes under direct visualization.
    • This procedure requires only local anesthesia.
    • HTA may be used in patients with irregularly shaped endometrial cavities and/or fibroids.
    • Vaginal and skin burns are the most reported complications.
  • Cryoablation26
    • Cryoablation is the use of liquid nitrogen to freeze the endometrium. The procedure is performed in approximately 10 minutes under ultrasonographic guidance.
    • Patients usually experience 1 week of watery vaginal discharge postprocedure.
    • Risks include perforation and suboptimal ablation of the entire uterine cavity.
  • Microwave endometrial ablation alternative27
    • Microwave endometrial ablation (MEA) uses high-frequency microwave energy to cause rapid but shallow heating of the endometrium.
    • Microwaves are selected so that they do not destroy beyond 6 mm in depth.
    • MEA requires 3 minutes of time and only local anesthetic. It is proving to be as effective as TCRE.
    • This procedure was developed and has been used in Europe since 1996.
  • Radiofrequency electricity26
    • NovaSure system is a detailed microprocessor-based unit with a bipolar gold mesh electrode array.
    • It contains a system for determining uterine integrity based upon the injection of CO 2 .
    • The device is placed transcervically, the array is opened and electrical energy is applied for 80-90 seconds, desiccating the endometrium.
  • Myomectomy28
    • Myomectomy can be useful in women who wish to retain their uterus and/or fertility.
    • Since myomectomy can be associated with large blood loss, this procedure is often reserved for cases of a single or few myomas.
    • Risks include large blood loss or recurrence.
  • Hysterectomy6 ,29
    • Hysterectomy provides definitive cure for menorrhagia.
    • This procedure is more expensive and results in greater morbidity than ablative procedures.
    • The mortality rate ranges from 0.1-1.1 cases per 1000 procedures.
    • The morbidity rate is usually 40%.
    • Risks include those usually associated with major surgery.

A 2005 Cochrane Review (updated in 2009) concluded that "overall the existing evidence suggests that success rates and complication profiles of newer techniques of ablation compare favourably with TCRE, although technical difficulties with new equipment need to be ironed out."27 ,30

Endometrial ablation or resection preparation

  • A trial of medical therapy should have failed in patients considered for this therapy.
  • The endometrium should be properly sampled and evaluated before surgery.
  • Patients should be pretreated with danazol or a GnRH analogue for 4-12 weeks before surgery to atrophy the endometrium, reducing surgical difficulty and time.
  • Success rates are similar to laser ablation techniques.

Medication

Acute menorrhagia requires prompt medical intervention. This is bleeding that will compromise an untreated patient.

Acute menorrhagia requires prompt medical interve...

Acute menorrhagia requires prompt medical intervention. This is bleeding that will compromise an untreated patient.


Successful treatment of chronic menorrhagia is highly dependent on a thorough understanding of the exact etiology. For instance, acute bleeding postpartum does not respond to progesterone therapy, while anovulatory bleeding worsens with high-dose estrogen.

Successful treatment of chronic menorrhagia is hi...

Successful treatment of chronic menorrhagia is highly dependent on a thorough understanding of the exact etiology. For instance, acute bleeding postpartum does not respond to progesterone therapy, while anovulatory bleeding worsens with high-dose estrogen.

 

Flow chart continued from Media file 2.

 

Nonsteroidal anti-inflammatory drugs

Block formation of prostacyclin, an antagonist of thromboxane, which is a substance that accelerates platelet aggregation and initiates coagulation. Prostacyclin is produced in increased amounts in menorrhagic endometrium. Because NSAIDs inhibit blood prostacyclin formation, they might effectively decrease uterine blood flow.

 

Naproxen (Anaprox, Naprelan, Naprosyn)

Used for relief of mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing activity of cyclooxygenase, which is responsible for prostaglandin synthesis.

Adult

250-500 mg PO bid; give at last 2 d and first 3 d of cycle, for a total of 5 d

Pediatric

Not established

Probenecid may increase toxicity of NSAIDs; coadministration with ibuprofen might decrease effects of loop diuretics; coadministration with anticoagulants might prolong PT (watch for signs of bleeding); might increase serum lithium levels and risk of methotrexate toxicity (eg, stomatitis, bone marrow suppression, nephrotoxicity)

Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis might occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and might require discontinuation

 

Diclofenac (Cataflam)

Inhibits PG synthesis by decreasing activity of enzyme cyclooxygenase, which in turn decreases formation of PG precursors.

Adult

Initial: 100 mg PO once, then 50 mg PO tid

Pediatric

Not established

Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, concomitantly with ACE inhibitors; concomitant administration of low-dose aspirin may result in increased rate of GI ulceration or other complications compared to use of NSAIDs alone; clinical studies and postmarketing observations show that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients, and this response has been attributed to inhibition of renal prostaglandin synthesis; NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance

Use in persons with allergic reaction to aspirin/NSAIDs, such as swelling, asthma, hives, urticaria, or any forms of angioedema; active GI bleed; active ulcer

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

GI bleeding; anaphylaxis; renal or liver injury

Combination oral contraceptives

OCPs containing estrogen and progestin used to treat acute hemorrhagic uterine bleeding.

 

Ethinyl estradiol and a progestin derivative (Ovral, Ortho-Novum, Ovcon, Genora)

Reduce secretion of LH and FSH from the pituitary by decreasing amount of GnRH. Reduce pituitary production of gonadotropins and result in reduced LH and FSH with no ovulation.

Adult

1 tab PO qd for 3 wk; followed by a week of inactive pills, during which a withdrawal bleed generally occurs; repeat monthly

Pediatric

Not established

Hepatotoxicity might occur with concurrent administration of cyclosporine; concomitant use of rifampin, barbiturates, phenylbutazone, phenytoin sodium, and, possibly, griseofulvin, ampicillin, and tetracyclines might influence efficacy of oral contraceptives and increase amount of breakthrough bleeding and menstrual irregularity

Documented hypersensitivity; pregnancy; active or inactive thrombophlebitis or thromboembolic disorders, cerebral vascular disease, myocardial infarction, coronary artery disease, or a past history of these disorders; known or suspected breast cancer; known or suspected genital cancer; history of cholestatic jaundice in pregnancy or jaundice with prior pill use; past or present liver tumors

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Complete physical examination, documentation of recent Pap smear test, and family history recommended; pay special attention to blood pressure, breasts, abdomen, and pelvic organs; repeat physical examination annually as long as patient is on hormonal therapy
Oral contraceptives can cause fluid retention (address any condition aggravated by this factor)
Monitor patients with epilepsy, migraine, asthma, or renal or cardiac dysfunction
History of psychic depression might be aggravated (observe patient closely)
Progestin compounds might elevate LDL levels, making control of hyperlipidemia more difficult (observe closely); certain forms of congenital hypertriglyceridemia might be aggravated by oral contraceptives, with resultant pancreatitis
Discontinue if jaundice develops
Contact lens wearers with visual changes should be examined by ophthalmologist
Patients might develop hypertension secondary to increase in angiotensinogen production (reevaluate blood pressure approximately 3 mo after initiating therapy in all patients)

Progestins

Occasional anovulatory bleeding that is not profuse or prolonged can be treated with progestins, antiestrogens given in pharmacologic doses. Inhibit estrogen-receptor replenishment and activate 17-hydroxysteroid dehydrogenase in endometrial cells, converting estradiol to the less-active estrone.

 

Medroxyprogesterone (Provera)/megestrol acetate/19-nortestosterone derivative

Provera: Short-acting synthetic progestin. Works as an antiestrogen by minimizing estrogen effects on target cells. Endometrium is maintained in an atrophic state. Effective against hyperplasia and has modest effects on serum lipids (ie, lowering HDL)
Megestrol acetate: May be substituted for Provera. Is active against hyperplasia without significantly altering serum lipid levels.
Derivatives of 19-nortestosterone: Potent progestins used in oral contraceptives. Have partial androgenic properties and lower HDL cholesterol levels.

Adult

Provera: 10 mg/d PO for 10 d monthly
Provera for atypical hyperplasia: 10 mg/d PO for 12 d once
Megestrol acetate: 40-80 mg PO for 10 d monthly
Megestrol acetate for atypical hyperplasia: 40-80 mg PO for 12 d once
Derivatives of 19-nortestosterone: Used in oral combination birth control pills; doses vary from 0.075-0.35 mg/pill depending on derivative
Derivatives of 19-nortestosterone for atypical hyperplasia: 5 mg/d for 12 d once

Pediatric

Not established

Decreases aminoglutethimide efficacy

Documented hypersensitivity; cerebral apoplexy; undiagnosed vaginal bleeding; thrombophlebitis; liver dysfunction; missed abortion; known or suspected malignancy of breast or genital tract; active or past history of thrombophlebitis, thromboembolic disorders, or cerebral apoplexy (based on past experience with combination oral contraceptive medications; little data suggest that progestin therapy used without estrogen is associated with an increased risk of thrombotic events)

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Caution in asthma, depression, renal or cardiac dysfunction, or thromboembolic disorders; perform complete physical examination, document recent Papanicolaou smear, and take family history before therapy; give special attention to blood pressure, breasts, abdomen, and pelvic organs; repeat physical examination annually; progestins can cause fluid retention (address any condition aggravated by this factor); monitor patients with epilepsy, migraine, asthma, renal or cardiac dysfunction, and history of psychic depression

Gonadotropin-releasing hormone agonists

Work by reducing concentration of GnRH receptors in the pituitary via receptor down-regulation and induction of postreceptor effects, which suppress gonadotropin release. After an initial gonadotropin release associated with rising estradiol levels, gonadotropin levels fall to castrate levels, with resultant hypogonadism. This form of medical castration is very effective in inducing amenorrhea, thus breaking the ongoing cycle of abnormal bleeding in many anovulatory patients.

 

Leuprolide (Lupron)

Suppresses ovarian and testicular steroidogenesis by decreasing LH and FSH levels.

Adult

3.5-7.5 mg IM monthly for 3-6 mo

Pediatric

Not established

None reported

Documented hypersensitivity; undiagnosed vaginal bleeding and spinal cord compression

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Urinary tract obstruction, tumor flare, and bone pain may occur; monitor patients for weakness and paresthesias; may cause menopauselike symptoms; may cause bone demineralization and/or reduction in HDL cholesterol if given for > 6 mo

Androgens

Certain androgenic preparations have been used historically to treat mild-to-moderate bleeding, particularly in ovulatory patients with abnormal uterine bleeding. Use might stimulate erythropoiesis and clotting efficiency. Alters endometrial tissue so that it becomes inactive and atrophic.

 

Danazol (Danocrine)

Synthetic steroid analog with strong antigonadotropic activity (inhibits LH and FSH) and weak androgenic action. Competes with androgen and progesterone at receptor level, resulting in amenorrhea within 3 mo.

Adult

100-400 mg PO qd for 3 mo

Pediatric

Not established

Prolongation of PT occurs in patients who are on warfarin; carbamazepine levels might rise with concurrent use; might interfere with laboratory determinations of DHEA, androstenedione, and testosterone

Documented hypersensitivity; breastfeeding; seizure disorders; markedly impaired hepatic function or porphyria

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Caution in renal, hepatic (may elevate serum transaminase levels), or cardiac insufficiency and in seizure disorders; androgen effects may cause hirsutism, acne, lowering of voice, or decreased breast size

Arginine vasopressin derivatives

Indicated in patients with thromboembolic disorders.

 

Desmopressin (DDAVP)

Has been used to treat abnormal uterine bleeding in patients with coagulation defects. Transiently elevates factor VIII and von Willebrand factor.

Adult

0.3 mcg/kg in 50 mL NS IV push (15 min)

Pediatric

Not established

Coadministration with demeclocycline and lithium decrease effects; fludrocortisone and chlorpropamide increase effects

Documented hypersensitivity; platelet-type von Willebrand disease

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Avoid overhydration in patients using desmopressin to benefit from its hemostatic effects; may cause platelet aggregation in von Willebrand type IIB

Estrogens

Effective in controlling acute, profuse bleeding. Exerts a vasospastic action on capillary bleeding by affecting the level of fibrinogen, factor IV, and factor X in blood and platelet aggregation and capillary permeability. Estrogen also induces formation of progesterone receptors, making subsequent treatment with progestins more effective.

 

Conjugated equine estrogen (Premarin)

Only controls bleeding acutely but does not treat underlying cause. Appropriate long-term therapy can be administered once the acute episode has passed.

Adult

Acute bleeding: 25 mg IV q4h for a maximum of 48 h; 2.5 mg PO q6h for a maximum of 48 h

Pediatric

Not established

Follow-up

Complications

  • Treatment of menorrhagia must be individualized to treat each patient's specific symptoms. Cost, dosing, and patient compliance can play major roles.
  • If bleeding does not subside within the expected time frame, have the patient keep a menstrual calendar to better assess the resulting bleeding pattern.
  • If a specific treatment fails, investigate all possibilities, including noncompliance, medication dosing, diagnosis, patient age, and comorbid conditions.

Prognosis

With proper workup, diagnosis, treatment, and follow-up care, prognosis is excellent.

Patient Education

  • Reassure patients that most bleeding stops, but not immediately. Provide literature on the treatment of choice, including expectations and adverse effects.
  • Many patients appreciate reassurance that they do not have cancer and are not alone in their plight.
  • Reassure patients who experience a treatment failure that other options are available

Medicolegal Pitfalls

  • Every patient presenting with uterine bleeding should first undergo pregnancy testing. Threatened or incomplete abortion, ectopic pregnancy, or retained products of conception must be considered before any imaging studies may be ordered.
  • Every high-risk or postmenopausal patient with uterine bleeding first must be evaluated for endometrial or other gynecological malignancy.
  • When treating patients with progestin therapy of any form, they must be informed that this is not a form of birth control. Pregnancy is possible, especially if ovulation is induced by the cycling of the progesterone.
  • All medications and procedures must be administered only after informed consent of all benefits and risks.
 

References

  1. HALLBERG L, NILSSON L. DETERMINATION OF MENSTRUAL BLOOD LOSS. Scand J Clin Lab Invest . 1964;16:244-8. [Medline] .

  2. Goldrath MH. Hysteroscopic endometrial ablation. Obstet Gynecol Clin North Am . Sep 1995;22(3):559-72. [Medline] .

  3. Fraser IS, Warner P, Marantos PA. Estimating menstrual blood loss in women with normal and excessive menstrual fluid volume. Obstet Gynecol . Nov 2001;98(5 Pt 1):806-14. [Medline] .

  4. Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol . May 2004;190(5):1216-23. [Medline] .

  5. Lentz GM. Abnormal Uterine Bleeding. In: Katz VL, Lentz GM, Lobo RA, Gershenson DM. Comprehensive Gynecology . 5th. Philadelphia, PA: Mosby; 2007:915-932.

  6. Wright RC. Hysterectomy: past, present, and future. Obstet Gynecol . Apr 1969;33(4):560-3. [Medline] .

  7. Wilansky DL, Greisman B. Early hypothyroidism in patients with menorrhagia. Am J Obstet Gynecol . Mar 1989;160(3):673-7. [Medline] .

  8. Noorhasan DJ, Weiss G. Perimenarchal menorrhagia: evaluation and management. J Pediatr . Jan/2010;156 (1):162. [Medline][Full Text] .

  9. Glasser MH, Zimmerman JD. The HydroThermAblator system for management of menorrhagia in women with submucous myomas: 12- to 20-month follow-up. J Am Assoc Gynecol Laparosc . Nov 2003;10(4):521-7. [Medline] .

  10. Collins J, Schlesselman H. Hormone Replacement Therapy and Endometrial Cancer. In: Lobo R. Treatment of the Postmenopausal Woman . Philadelphia, PA: Lippincott, Williams & Wilkins; 1999.

  11. [Guideline] James AH, Kouides PA, Abdul-Kadir R, Edlund M, Federici AB, Halimeh S, et al. Von Willebrand disease and other bleeding disorders in women: Consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol . May 28 2009;[Medline] .

  12. Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet . Feb 14 1998;351(9101):485-9. [Medline] .

  13. Dodson MG. Use of transvaginal ultrasound in diagnosing the etiology of menometrorrhagia. J Reprod Med . May 1994;39(5):362-72. [Medline] .

  14. Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer . Oct 15 2000;89(8):1765-72. [Medline] .

  15. Shaw RW. Assessment of medical treatments for menorrhagia. Br J Obstet Gynaecol . Jul 1994;101 Suppl 11:15-8. [Medline] .

  16. Jurema M, Zacur H. Menorrhagia. UpToDate. Available at http://www.uptodateonline.com/online/content/topic.do?topicKey=gen_gyne/4741&selectedTitle=1~138&source=search_result . Accessed March 29, 2009.

  17. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol . Feb 1991;31(1):66-70. [Medline] .

  18. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol . Aug 1990;97(8):690-4. [Medline] .

  19. Rauramo I, Elo I, Istre O. Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection. Obstet Gynecol . Dec 2004;104(6):1314-21. [Medline] .

  20. Results unpublished, information provided from press release. FDA Approves Intrauterine Device for Heavy Menstrual Bleeding. Available at http://www.prnewswire.com/news-releases/fda-approves-new-indication-for-mirenar-to-treat-heavy-menstrual-bleeding-in-iud-users-63164722.html .

  21. DeCherney A, Polan ML. Hysteroscopic management of intrauterine lesions and intractable uterine bleeding. Obstet Gynecol . Mar 1983;61(3):392-7. [Medline] .

  22. Chullapram T, Song JY, Fraser IS. Medium-term follow-up of women with menorrhagia treated by rollerball endometrial ablation. Obstet Gynecol . Jul 1996;88(1):71-6. [Medline] .

  23. Meyer WR, Walsh BW, Grainger DA, et al. Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstet Gynecol . Jul 1998;92(1):98-103. [Medline] .

  24. Garza-Leal J, Pena A, Donovan A, et al. Clinical Evaluation of a Third-Generation Thermal Uterine Balloon Therapy System for Menorrhagia Coupled with Curettage. J Minim Invasive Gynecol . Jan 2010;17(1):82-90. [Medline][Full Text] .

  25. Goldrath MH. Evaluation of HydroThermAblator and rollerball endometrial ablation for menorrhagia 3 Years after treatment. J Am Assoc Gynecol Laparosc . Nov 2003;10(4):505-11. [Medline] .

  26. [Guideline] ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 81, May 2007. Obstet Gynecol . May 2007;109(5):1233-48. [Medline] .

  27. [Best Evidence] Lethaby A, Hickey M, Garry R. Endometrial destruction techniques for heavy menstrual bleeding. Cochrane Database Syst Rev . Oct 19 2005;CD001501. [Medline][Full Text] .

  28. Learman LA, Summitt RL Jr, Varner RE, Richter HE, Lin F, Ireland CC. Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: clinical outcomes in the medicine or surgery trial. Obstet Gynecol . May 2004;103(5 Pt 1):824-33. [Medline] .

  29. Showstack J, Lin F, Learman LA, Vittinghoff E, Kuppermann M, Varner RE. Randomized trial of medical treatment versus hysterectomy for abnormal uterine bleeding: resource use in the Medicine or Surgery (Ms) trial. Am J Obstet Gynecol . Feb 2006;194(2):332-8. [Medline] .

  30. Lethaby A, Hickey M, Garry R, Penninx J. Endometrial resection / ablation techniques for heavy menstrual bleeding. Cochrane Database Syst Rev . Oct 7 2009;CD001501. [Medline] .

Mon, 19 Jul 2010 @00:01

Buat nama web sesukanya

Cek Nama Domain ?

image

Ask2obgyn

ask2obgyn@gmail.com

Mesin penerjemah
FACEBOOK
KUNJUNGAN

Daftar link
Video dan Gambar
Copyright © 2017 Bung Kemas · All Rights Reserved